{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-26-000007","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.007324+00:00","generated_at":"2026-05-16T00:22:36.082247+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcus Biosciences reports Q4 net loss $106M; casdatifan shows 45% cORR in late-line kidney cancer","bullets":["Q4 2025 net loss $106M vs $94M YoY; revenue $33M; cash, equivalents & marketable securities $1.0B.","Casdatifan 100mg QD in late-line ccRCC: confirmed ORR 45.2%, median PFS 15.1 months (Jan 30, 2026 cut).","Full-year 2026 GAAP revenue guidance $45-55M; R&D expenses expected to decrease meaningfully.","Phase 3 PEAK-1 (casdatifan + cabozantinib) enrolling globally; 1L Phase 3 planned by end 2026.","First inflammation program (oral MRGPRX2 antagonist) to enter clinic in 2026; oral TNF inhibitor in late 2026/early 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-26-000007","json":"https://secwatch.observer/filing/0001724521-26-000007.json","markdown":"https://secwatch.observer/filing/0001724521-26-000007.md","text":"https://secwatch.observer/filing/0001724521-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000007/0001724521-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000007/rcus-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:22:36.082247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}